Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)

Medicare covers the Abbott RealTime IDH1 and IDH2 assays (unmodified Abbott kits) to identify IDH1 or IDH2 mutations in adult patients with acute myeloid leukemia to guide treatment with ivosidenib (TIBSOVO) or enasidenib (IDHIFA), respectively. Claims must use CPT 81120 (IDH1) or 81121 (IDH2) with 1 unit of service, include the appropriate DEX Z-Code identifier and an appropriate ICD-10-CM diagnosis code, and modified tests require prior MolDX Technical Assessment before submission.

"Abbott RealTime IDH1 (Abbott Molecular) is covered for Medicare reimbursement to identify IDH1 mutations in adult patients with acute myeloid leukemia (AML) to aid selection of treatment with ivosi..."

Sign up to see full coverage criteria, indications, and limitations.